Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Blarcamesine hydrochloride by Anavex Life Sciences for Fragile X Syndrome: Likelihood of Approval
Blarcamesine hydrochloride is under clinical development by Anavex Life Sciences and currently in Phase I for Fragile X Syndrome. According...
Data Insights
Blarcamesine hydrochloride by Anavex Life Sciences for Infantile Spasm (West Syndrome): Likelihood of Approval
Blarcamesine hydrochloride is under clinical development by Anavex Life Sciences and currently in Phase I for Infantile Spasm (West Syndrome)....